22 juni 2020: zie ook dit artikel:

https://kanker-actueel.nl/helicobacter-pylori-behandeling-met-amoxicillin-en-omeprazole-en-vitaminesuppletie-met-c-e-en-selenium-en-knoflook-verminderen-overlijden-aan-maagkanker-en-voorkomen-ontstaan-van-maagkanker.html

9 december 2016: Bron: Journal of International Medical Research April 2015 vol. 43 no. 2 204-216

Wanneeer mensen met aantoonbare maagdysplasie daarvoor naast omeprazol en sucralfaat ook ATRA - all-trans-retinoic acid nemen dan verminderen zij daarmee het risico op vorming van verdere kwaadaardige maagdysplasie en indirect daarmee maagkanker in vergelijking met alleen omeprazol en sucrosalfaat.

Dit blijkt uit een dubbelblinde gerandomiseerde studie met totaal 122 patiënten: 63 patiënten in de ATRA groep en 59 in de controle groep. In de ATRA groep werd de dysplasia verminderd of vernietigd bij 43 van de 63 patiënten (68%) vergeleken bij 22 van de 59 patiënten (37%) in de controle groep; Echter vorming van inwendige metaplasie (IM) werd niet beinvloed door geen van beide behandelingen. ATRA was wel gerelatereed aan een uidelijke verhoging van de zogeheten Rb expressie en verminderde HER2 expressie in het maagweefsel.

ATRA bij maagdysplasie

ATRA blijkt dus indirect maagkanker te kunnen voorkomen.

Het volledige studierapport: Addition of all-trans-retinoic acid to omeprazole and sucralfate therapy improves the prognosis of gastric dysplasia is gratis in te zien.

Hier het abstract van de studie:

The use of conventional therapy plus ATRA for gastric dysplasia was associated with improved efficacy compared with conventional therapy alone. It was also accompanied by increased Rb expression and decreased HER2 expression in gastric mucosa. The addition of ATRA to conventional therapy for gastritis may improve the prognosis of gastric dysplasia.

2015 Apr;43(2):204-16. doi: 10.1177/0300060514559791. Epub 2015 Jan 28.

Addition of all-trans-retinoic acid to omeprazole and sucralfate therapy improves the prognosis of gastric dysplasia.

Jin J¹, Li X¹, Xing L², Chang Y³, Wu L¹, Jin Z¹, Su X¹, Bai Y¹, Zheng Y¹, Jiang Y³, Zhao X¹, Lu L¹, Gao Q⁴.

Author information

¹Department of Gastroenterology and Hepatology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
²Department of Pathology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
³Clinical Laboratory, First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
⁴Department of Gastroenterology and Hepatology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China gaoq@mail.haust.edu.cn.

Abstract

OBJECTIVE:

To investigate the efficacy of all-trans retinoic acid (ATRA) in human gastric dysplasia.

METHODS:

In this double-blind study, patients with precancerous gastric dysplasia with or without intestinal metaplasia (IM) received either conventional treatment consisting of omeprazole and sucralfate (control group) or conventional treatment plus ATRA. Gastric mucosal biopsies were performed before and after drug treatment and were analysed histologically; expression of retinoblastoma (Rb) protein and HER2 protein in gastric mucosa were measured using immunohistochemistry.

RESULTS:

A total of 122 patients were included in the study, 63 in the ATRA group and 59 in the control group. In the ATRA group, dysplasia was attenuated in 43 out of 63 patients (68%) compared with 22 out of 59 patients (37%) in the control group; however, IM was not affected by treatment in either group. ATRA treatment was associated with significantly increased Rb expression and decreased HER2 expression in gastric mucosa.

CONCLUSIONS:

The use of conventional therapy plus ATRA for gastric dysplasia was associated with improved efficacy compared with conventional therapy alone. It was also accompanied by increased Rb expression and decreased HER2 expression in gastric mucosa. The addition of ATRA to conventional therapy for gastritis may improve the prognosis of gastric dysplasia.